Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Literature DB >> 20544403

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Jae Hoon Lee¹, Dong Soon Lee, Je Jung Lee, Yoon Hwan Chang, Jong Youl Jin, Deog-Yeon Jo, Soo Mee Bang, Hyo Jung Kim, Jin Seok Kim, Kihyun Kim, Hyeon Seok Eom, Chang Ki Min, Sung Soo Yoon, Sun Hee Kim, Cheolwon Suh, Kyung Sam Cho.

Abstract

Entities: Disease

Mesh：

Year: 2010 PMID： 20544403 DOI： 10.1007/s12185-010-0617-6

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

× No keyword cloud information.

24 in total

1. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

Authors: Soo-Mee Bang; Jae Hoon Lee; Sung-Soo Yoon; Seonyang Park; Chang-Ki Min; Chun-Choo Kim; Cheolwon Suh; Sang Kyun Sohn; Yoo-Hong Min; Je-Jung Lee; Kihyun Kim; Chu-Myong Seong; Hwi-Joong Yoon; Kyung Sam Cho; Deog-Yeon Jo; Kyung Hee Lee; Na-Ri Lee; Chul Soo Kim
Journal: Int J Hematol Date: 2006-05 Impact factor: 2.490

2. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

Authors: Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo Ryoo; Young Rok Do; Jong-Youl Jin; Hye Jin Kang; Gyeong-Won Lee; Moon Hee Lee; Hyeok Shim; Kihyun Kim; Sung-Soo Yoon; Soo Mee Bang; Ho Young Kim; Je-Jung Lee; Jinny Park; Dong Soon Lee; Jae-Hoon Lee
Journal: Ann Hematol Date: 2010-03-27 Impact factor: 3.673

3. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.

Authors: Deok-Hwan Yang; Yeo-Kyeoung Kim; Sang-Kyun Sohn; Joo-Seop Chung; Young-Don Joo; Jae-Hoon Lee; Jung-Lim Lee; Jae-Sook Ahn; Joon-Ho Moon; Ho-Jin Shin; Young-Jin Choi; Won-Sik Lee; Hyeoung-Joon Kim; Je-Jung Lee
Journal: Clin Lymphoma Myeloma Leuk Date: 2010-02

4. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.

Authors: Hawk Kim; Hee-Jung Sohn; Shin Kim; Kihyun Kim; Jae Hoon Lee; Soo-Mee Bang; Dong-Hwan Kim; Sang Kyun Sohn; Je-Jung Lee; Cheolwon Suh
Journal: Biol Blood Marrow Transplant Date: 2006-08 Impact factor: 5.742

5. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

Authors: Hyeon-Seok Eom; Yeo-Kyeoung Kim; Joo-Seop Chung; Kihyun Kim; Hyo Jung Kim; Ho Young Kim; Jong-Youl Jin; Young-Rok Do; Suk-Joong Oh; Cheolwon Suh; Chu-Myong Seong; Chul Soo Kim; Dong Soon Lee; Jae Hoon Lee
Journal: Ann Hematol Date: 2009-12-10 Impact factor: 3.673

6. [Association of NQO1 Polymorphism with Multiple Myeloma Risk in Koreans.].

Authors: Seong Ho Kang; Tae Young Kim; Ho Young Kim; Yun Kyung Lee; Hee Won Moon; Dong Soon Lee; Han Ik Cho
Journal: Korean J Lab Med Date: 2006-04

7. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.

Authors: Youngil Koh; Soo-Mee Bang; Jae Hoon Lee; Hwi-Joong Yoon; Young-Rok Do; Hun-Mo Ryoo; Nari Lee; Seok Jin Kim; Kihyun Kim; Sung-Soo Yoon; Jong-Ho Won; Yeung-Chul Mun; Moon-Hee Lee; Ki-Hyun Rhee; Hyo-Jung Kim; Hyeonseok Eom; Min Kyoung Kim; Hyun Chun Shin
Journal: Ann Hematol Date: 2009-08-25 Impact factor: 3.673

8. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

Authors: Je-Jung Lee; Bo-Hwa Choi; Hyun-Kyu Kang; Myong-Suk Park; Jung-Sun Park; Sang-Ki Kim; Thanh-Nhan Nguyen Pham; Duck Cho; Jong-Hee Nam; Young-Jin Kim; Joon-Haeng Rhee; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Ik-Joo Chung
Journal: Leuk Lymphoma Date: 2007-10

9. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.

Authors: Deok-Hwan Yang; Jung-Sun Park; Chun-Ji Jin; Hyun-Kyu Kang; Jong-Hee Nam; Joon-Haeng Rhee; Yeo-Kyeoung Kim; Sang-Young Chung; So-Jin-Na Choi; Hyeoung-Joon Kim; Ik-Joo Chung; Je-Jung Lee
Journal: Leuk Res Date: 2008-10-15 Impact factor: 3.156

10. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.

Authors: Tae Young Kim; Jongmin Park; Bora Oh; Hyun Jung Min; Tae-Sook Jeong; Jae Hoon Lee; Cheolwon Suh; June-Won Cheong; Hyo Jung Kim; Sung-Soo Yoon; Seung Bum Park; Dong Soon Lee
Journal: Br J Haematol Date: 2009-06-03 Impact factor: 6.998

14 in total

1. Prevalence of monoclonal gammopathy of undetermined significance in Thailand.

Authors: Phandee Watanaboonyongcharoen; Thanyaphong Na Nakorn; Ponlapat Rojnuckarin; Panisinee Lawasut; Tanin Intragumtornchai
Journal: Int J Hematol Date: 2012-01-12 Impact factor: 2.490

2. Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?

Authors: Je-Jung Lee
Journal: Korean J Hematol Date: 2010-09-30

Review 3. Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.

Authors: Hyo Jung Kim; Sung-Soo Yoon; Hyeon Seok Eom; Kihyun Kim; Jin Seok Kim; Je-Jung Lee; Soo-Mee Bang; Chang-Ki Min; Joon Seong Park; Jae-Hoon Lee
Journal: Blood Res Date: 2015-03-24

4. Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.

Authors: Seok Jin Kim; Soo-Mee Bang; Yoon Seok Choi; Deog-Yeon Jo; Jin Seok Kim; Hyewon Lee; Hyeon Seok Eom; Dok Hyun Yoon; Cheolwon Suh; Je-Jung Lee; Junshik Hong; Jae Hoon Lee; Youngil Koh; Kihyun Kim; Sung-Soo Yoon; Chang-Ki Min
Journal: Blood Res Date: 2016-09-23

5. Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan.

Authors: Jia-Hong Chen; Chi-Hsiang Chung; Yung-Chih Wang; Shun-Neng Hsu; Wen-Yen Huang; Wu-Chien Chien
Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240

6. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.

Authors: Min Kyoung Kim; Kihyun Kim; Chang-Ki Min; Jae-Yong Kwak; Sang-Byung Bae; Sung-Soo Yoon; Je-Jung Lee; Ki Hwan Kim; Seung-Hyun Nam; Yeung-Chul Mun; Hyo Jung Kim; Sung Hwa Bae; Ho-Jin Shin; Jung-Hee Lee; Joon Seong Park; Seong Hyun Jeong; Mark Hong Lee; Yang-Soo Kim; Ho Sup Lee; Keon Woo Park; Won-Sik Lee; Sang Min Lee; Jeong-Ok Lee; Myung Soo Hyun; Deog Yeon Jo; Sung-Nam Lim; Jae Hoon Lee; Do-Yeun Cho; Young Rok Do; Jeong-A Kim; Seong Kyu Park; Jin Seok Kim; Soo-Jeong Kim; Hawk Kim; Hyeon Gyu Yi; Joon Ho Moon; Chul Won Choi; Sung-Hyun Kim; Young-Don Joo; Hoon-Gu Kim; Byung Soo Kim; Moo-Rim Park; Moo-Kon Song; Su-Youn Kim
Journal: Oncotarget Date: 2017-06-06

7. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

Authors: Jin Lu; Jae H Lee; Shang-Yi Huang; Lugui Qiu; Je-Jung Lee; Ting Liu; Sung-Soo Yoon; Kihyun Kim; Zhi X Shen; Hyeon S Eom; Wen M Chen; Chang K Min; Hyo J Kim; Jeong O Lee; Jae Y Kwak; Wai Yiu; Guang Chen; Annette Ervin-Haynes; Cyrille Hulin; Thierry Facon
Journal: Br J Haematol Date: 2017-01-20 Impact factor: 6.998

Review 8. Recent advances in multiple myeloma: a Korean perspective.

Authors: Junshik Hong; Jae Hoon Lee
Journal: Korean J Intern Med Date: 2016-09-01 Impact factor: 2.884

9. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.

Authors: Na An; Xin Li; Man Shen; Shilun Chen; Zhongxia Huang
Journal: World J Surg Oncol Date: 2015-08-07 Impact factor: 2.754

10. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.

Authors: Ja Min Byun; Dong-Yeop Shin; Junshik Hong; Inho Kim; Hyun Kyung Kim; Dong Soon Lee; Youngil Koh; Sung-Soo Yoon
Journal: Cancer Med Date: 2018-01-29 Impact factor: 4.452